APELLIS PHARMACTDL (Germany) Probability of Future Stock Price Finishing Over 50.86

1JK Stock  EUR 31.22  0.02  0.06%   
APELLIS PHARMACTDL's future price is the expected price of APELLIS PHARMACTDL instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of APELLIS PHARMACTDL 0001 performance during a given time horizon utilizing its historical volatility. Check out APELLIS PHARMACTDL Backtesting, APELLIS PHARMACTDL Valuation, APELLIS PHARMACTDL Correlation, APELLIS PHARMACTDL Hype Analysis, APELLIS PHARMACTDL Volatility, APELLIS PHARMACTDL History as well as APELLIS PHARMACTDL Performance.
  
Please specify APELLIS PHARMACTDL's target price for which you would like APELLIS PHARMACTDL odds to be computed.

APELLIS PHARMACTDL Target Price Odds to finish over 50.86

The tendency of APELLIS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over € 50.86  or more in 90 days
 31.22 90 days 50.86 
near 1
Based on a normal probability distribution, the odds of APELLIS PHARMACTDL to move over € 50.86  or more in 90 days from now is near 1 (This APELLIS PHARMACTDL 0001 probability density function shows the probability of APELLIS Stock to fall within a particular range of prices over 90 days) . Probability of APELLIS PHARMACTDL 0001 price to stay between its current price of € 31.22  and € 50.86  at the end of the 90-day period is about 9.88 .
Assuming the 90 days horizon APELLIS PHARMACTDL has a beta of 0.75. This suggests as returns on the market go up, APELLIS PHARMACTDL average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding APELLIS PHARMACTDL 0001 will be expected to be much smaller as well. Additionally APELLIS PHARMACTDL 0001 has an alpha of 0.1789, implying that it can generate a 0.18 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   APELLIS PHARMACTDL Price Density   
       Price  

Predictive Modules for APELLIS PHARMACTDL

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as APELLIS PHARMACTDL 0001. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
27.2031.2235.24
Details
Intrinsic
Valuation
LowRealHigh
25.7729.7933.81
Details

APELLIS PHARMACTDL Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. APELLIS PHARMACTDL is not an exception. The market had few large corrections towards the APELLIS PHARMACTDL's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold APELLIS PHARMACTDL 0001, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of APELLIS PHARMACTDL within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.18
β
Beta against Dow Jones0.75
σ
Overall volatility
2.95
Ir
Information ratio 0.04

APELLIS PHARMACTDL Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of APELLIS PHARMACTDL for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for APELLIS PHARMACTDL 0001 can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
APELLIS PHARMACTDL had very high historical volatility over the last 90 days
The company reported the revenue of 113.05 M. Net Loss for the year was (460.28 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
APELLIS PHARMACTDL 0001 has accumulated about 599.01 M in cash with (239.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.89.
Over 89.0% of the company shares are owned by institutions such as pension funds

APELLIS PHARMACTDL Technical Analysis

APELLIS PHARMACTDL's future price can be derived by breaking down and analyzing its technical indicators over time. APELLIS Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of APELLIS PHARMACTDL 0001. In general, you should focus on analyzing APELLIS Stock price patterns and their correlations with different microeconomic environments and drivers.

APELLIS PHARMACTDL Predictive Forecast Models

APELLIS PHARMACTDL's time-series forecasting models is one of many APELLIS PHARMACTDL's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary APELLIS PHARMACTDL's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about APELLIS PHARMACTDL 0001

Checking the ongoing alerts about APELLIS PHARMACTDL for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for APELLIS PHARMACTDL 0001 help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
APELLIS PHARMACTDL had very high historical volatility over the last 90 days
The company reported the revenue of 113.05 M. Net Loss for the year was (460.28 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
APELLIS PHARMACTDL 0001 has accumulated about 599.01 M in cash with (239.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.89.
Over 89.0% of the company shares are owned by institutions such as pension funds

Other Information on Investing in APELLIS Stock

APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.